0001104659-26-059743
SEC filingImproved operating and net losses reflect disciplined expense management amid exhausted NIH grants, with reduced cash burn from operations extending liquidity runway into Q1 2028 per current operating plan.
Liquidity remains a key focus, with management stating that existing cash and cash equivalents will fund operating expenses and capital needs into Q1 2028 under the current plan. This extension supports progression of clinical trials, though prior and expected future losses will adversely affect stockholders' equity and working capital. Operating expenses have historically consisted solely of R&D and G&A costs, with R&D expected to rise as APR-1051 trials advance, balancing efficiency gains against pipeline investment needs.